Effectiveness of Atropine and Glycopyrrolate to Reduce Hyper Salivation With Ketamine Sedation

• Status: Completed
• Trial end date: 2011-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if the antisialagogues (anti-salivary agents), Atropine and Glycopyrrolate, are effective in reducing hypersalivation when sedating patients with Ketamine for procedural sedation in the emergency department or abscess clinic. The investigators will measure salivary flow rate by collecting oral secretions by oral suctioning over a 30 minute time period starting with the administration of Ketamine. The investigators hypothesize that patients who receive either atropine or glycopyrrolate will have fewer oral secretions than patients who receive placebo.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Craig J. Huang
• Treatments: Atropine; Glycopyrrolate; Ketamine

Criteria

Inclusion Criteria:

• Children age 6 months to 18 years (inclusive) presenting to Children's Medical Center Emergency Department or Abscess Clinic.

• Children whom the attending physician feels need procedural sedation with the intravenous medication, Ketamine.

Exclusion Criteria:

• Children who are ASA class III or greater.

• Children with an allergy or contraindication to ketamine, atropine or glycopyrrolate.

• Inability to tolerate oral suctioning.

• Any condition or situation whereby the patient would be unable to have his/her head turned to one side.

• Patient history of vomiting or diarrhea in the last 24 hours

• Patients who have taken an anti-sialogogue within the previous 24 hours.

• Patients that need to receive Midazolam or other benzodiazepines.